[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100531496":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":16,"locations":22,"responsibleParty":41,"collaborators":10,"id":44,"slug":45,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":10,"eligibilityCriteria":49,"healthyVolunteers":46,"sex":50,"minAge":51,"maxAge":10,"enrollmentInfo":52,"targetDuration":10,"studyType":55,"phases":10,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":25,"whyStopped":10,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},{"fullName":5,"class":6},"Hospital of Macerata","OTHER",[8,12,14],{"label":9,"type":10,"description":11,"interventionNames":10},"For ARON-3S: Patients with metachronous or de novo metastatic hormone\u002Fcastration-sensitive PCa",null,"Patients with metachronous or de novo metastatic hormone\u002Fcastration-sensitive PCa treated with ADT+ARSI or ADT+ARSI+docetaxel",{"label":13,"type":10,"description":10,"interventionNames":10},"For ARON-3Lu: Patients receiving Lutetium-177 PSMA for castration resistant PC (CRPC)",{"label":15,"type":10,"description":10,"interventionNames":10},"For ARON-3GEN: Patients treated with PARP inhibitors (alone or plus ARSI) for CRPC",[17],{"name":18,"role":19,"phone":20,"phoneExt":10,"email":21},"Matteo Santoni","CONTACT","+39 07332573752","sorgentoni.giulia@gmail.com",[23],{"facility":24,"status":25,"city":26,"state":27,"zip":28,"country":29,"countryCode":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":37},"Ospedale di Macerata","RECRUITING","Province of Macerata","Macerata","62100","Italy","IT",{"type":32,"coordinates":33},"Point",[34,35],13.45293,43.29789,{"lat":35,"lon":34},[38],{"name":39,"role":19,"phone":40,"phoneExt":10,"email":21},"Matteo Santoni, MD, PhD","+3907332573752",{"type":42,"investigatorFullName":18,"investigatorTitle":43,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Medical Doctor, Principal Investigator","100531496","aron-3-study-international-multicentric-retrospective-study-to-collect-global-experiences-in-the-treatment-of-patients-with-metastatic-pca-100531496",false,"NCT06200558","ARON-3 Study: International Multicentric Retrospective Study to Collect Global Experiences in the Treatment of Patients With Metastatic PCa","Inclusion Criteria:\n\n* Patients aged \\>18y\n* Cytological or Histologically confirmed diagnosis of PC\n* Histologically or radiologically confirmed diagnosis of metastatic disease and\n\nFor ARON-3S\n\n▪ Treatment with ADT + Apalutamide or ADT + enzalutamide or ADT + Abiraterone or ADT + Abiraterone + Docetaxel or ADT + Darolutamide + Docetaxel (patients treated with previous docetaxel - CHAARTED - resulted eligible)\n\nFor ARON-3Lu\n\n▪ Treatment with Luthetium-177-PSMA therapy for castration resistant PC\n\nFor ARON-3GEN\n\n* HRD POSITIVE STATUS\n* Treatment with PARP inhibitors for castration resistant PC. Treatment included: olaparib (as 1st, 2nd or 3rd line therapy), olaparib + abiraterone (as 1st line therapy) or niraparib + abiraterone (as 1st line therapy) or talazoparib + enzalutamide\n\nExclusion Criteria:\n\n* Patients without histologically confirmed diagnosis of PC\n* Patients without histologically or radiologically confirmed metastatic disease and\n\nFor ARON-3S\n\n▪ Patients treated with doublets or triplets not included in the list reported in the Inclusion Criteria Section\n\nFor ARON-3Lu\n\n▪ Patients treated with Luthetium-177-PSMA therapy for hormone\u002Fcastration sensitive PC\n\nFor ARON-3GEN\n\n* HRD NEGATIVE STATUS\n* Patients treated with PARP inhibitors alone or in combination regimens not included in the ARON-3GEN study","ALL","18 Years",{"count":53,"type":54},534,"ESTIMATED","OBSERVATIONAL","Study wants to explore real-world data in three distinct settings\n\n* Patients with metachronous or de novo mCSPC treated with ADT+ARSI or ADT+ARSI+docetaxel \\_ARON-3S\n* Patients receiving Lutetium-177 PSMA for mCRPC \\_ ARON-3Lu\n* Patients treated with PARP inhibitors (alone or combined with ARSI) for CRPC \\_ ARON-3GEN",[58],"Prostate Cancer",[60,61,62,63,64],"mCSPC","Lutetium-177 PSMA","PARP inhibitors","ADT","ARSI","2025-11-19",{"date":67,"type":68},"2025-11-26","ACTUAL",{"date":70,"type":68},"2024-01-31",{"date":72,"type":54},"2028-02-01",{"name":5,"class":6},1]